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EpigeneticsIntermittent hypoxia (IH) during sleep is one of themajor abnormalities occurring in patients suffering from ob-
structive sleep apnea (OSA), a highly prevalent disorder affecting 6–15% of the general population, particularly
among obese people. IH has been proposed as a major determinant of oncogenetically-related processes such
as tumor growth, invasion and metastasis. During the growth and expansion of tumors, fragmented DNA is re-
leased into the bloodstream and enters the circulation. Circulating tumor DNA (cirDNA) conserves the genetic
and epigenetic proﬁles from the tumor of origin and can be isolated from the plasma fraction. Here we report
a microarray-based epigenetic proﬁling of cirDNA isolated from blood samples of mice engrafted with TC1 epi-
thelial lung cancer cells and controls, which were exposed to IH during sleep (XenoIH group, n= 3) or control
conditions, (i.e., room air (RA); XenoRA group, n= 3) conditions. To prepare the targets for microarray hybrid-
ization,we applied a previously developedmethod that enriches themodiﬁed fraction of the cirDNAwithout am-
pliﬁcation of genomic DNA. Regions of differential cirDNAmodiﬁcation between the two groups were identiﬁed
by hybridizing the enriched fractions for each sample to Affymetrix GeneChip Human Promoter Arrays 1.0R. Mi-
croarray raw and processed data were deposited in NCBI's Gene Expression Omnibus (GEO) database (accession
number: GSE61070).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell
line/tissueMus musculus (C57BL/6J strain) injected with TC1 murine
lung tumor cells/plasmaSex Male
Sequencer or array
typeGeneChip Mouse Promoter Array 1.0R (Affymetrix,
Santa Clara, CA)Data format Raw and RMA-processed data
Experimental
factorsXenografted mice exposed to intermittent hypoxia (IH)
(n= 3, XenoIH group) or room air conditions (RA)
(n= 3, XenoRA group)Experimental
featuresMice engrafted with TC1 epithelial lung tumor cells were
exposed to IH or RA conditions. Large-scale cirDNA epigenetic
modiﬁcation proﬁles were assessed in plasma cirDNA samples
from xenografted mice exposed to IH or to RA conditions,
according to previously described methods [1]. After quality
control, data were analyzed using the Partek Genomic Suite
Software (PGS) (St. Louis, MO).Consent NA
Sample source
locationChicago, IL, United States of Americahe University of Chicago, 5721
60637, United States. Tel.: +1
nces I, University of Barcelona,
. This is an open access article under1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61070.2. Experimental design, materials and methods2.1. Experimental designFig. 1 provides a schematic representation of the design for the
full study, as previously reported [2]. Mice injected with tumor
TC1 cells and control mice were exposed to intermittent hypoxia
(IH) during sleep, or room air (RA) conditions (see below for de-
tails). Large scale DNA methylation proﬁles of circulating DNA
were produced in plasma cirDNA samples from xenografted mice
exposed to IH (XenoIH group, n = 3) or to RA (XenoRA group,
n = 3) conditions using a method that enriches the modiﬁed frac-
tion of the cirDNA without ampliﬁcation of genomic DNA [1]
(Fig. 2). Regions of differential cirDNA modiﬁcation between the
XenoIH and XenoRA group were identiﬁed by hybridizing the
enriched fractions for each sample to Affymetrix GeneChip Human
Promoter Array 1.0R.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Experimental setup for the full study. Xenografted and controlmicewere exposed to intermittent hypoxia (IH) during sleep—XenoIH andCtrlIH groups, and roomair (RA) conditions—
XenoRA and CtrlRA groups. cirDNAwas isolated from blood plasma and characterized by quantiﬁcation, fragment analysis and DNAmethylation proﬁling. In addition, genomic DNAwas iso-
lated from peripheral blood lymphocytes, tumor and skeletal muscle. DNAmethylation status of candidate loci was studied in plasma cirDNA and tissue genomic DNA by single locus analysis.
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2.2.1. Animals, hypoxic exposures, and epithelial lung tumor model
C57BL/6J male mice (7-week old) were acquired from Jackson Labo-
ratories (Bar Harbor, ME). Micewere pre-exposed during 2weeks to ei-
ther RA or IH during the daylight phase corresponding to the preferred
sleep period, and were then injected with 1 × 105 TC1 murine lung
tumor cells in the leftﬂank. The protocol for IH exposurewas previously
described by our group [3] and consisted of alternating cycles of 90 s (6%
fraction of inspired oxygen (FiO2) followed by 21% FiO2) for 12 h/day
(7 AM to 7 PM). With this paradigm, the oxyhemoglobin saturation at
the end of the hypoxic period reaches to 65%–72%mimicking that expe-
rienced by moderate to severe OSA patients [4]. For the rest of the day
(7 PM to 7 AM) the mice were in normoxic conditions (21% FiO2). Gas
mixture was electronically controlled by an internal analyzer which
can receive in real-time the O2 values inside of the chamber and can au-
tomatically modify by a computerized system of solenoid valves the gas
mixture to follow the programmed gas proﬁle. After 4 weeks from
tumor injection, mice were sacriﬁced and tumors excised and weighed.
All experimental procedures were approved by the Institutional Animal
Care and Use Committee of the University of Chicago.2.2.2. Plasma cirDNA and genomic DNA isolation
Blood sampleswere collected after being sacriﬁced and immediately
processed. The plasma fraction was separated by centrifugation andFig. 2. Method for cirDNA modiﬁcation epigenetic proﬁling. Universal DNA adaptors
(red blocks)were ligated to the ends of cirDNA fragments (green bars), followed by diges-
tionwith DNAmodiﬁcation-sensitive enzymes (HpaII,HinP1 andHpyCH4IV). cirDNA frag-
ments that survive enzymatic hydrolysis were ampliﬁed by adaptor-mediated PCR and
labeled with biotinylated nucleotides. During the PCR reaction, DNA polymerase extends
primers (dashed blue lines) according to its processivity and the optimized reaction con-
ditions. PCR products will be obtained only from undigested short templates that have li-
gated adaptors at both sides. In longer template (as expected from genomic DNA), the
DNA polymerase cannot extend primers in the distance between 5′ and 3′ adaptors and
therefore they will not be ampliﬁed. This enriched differentially modiﬁed DNA fraction
was hybridized to Affymetrix GeneChip Human Promoter Array 1.0R, which contains
more than 25,000 promoter regions.
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(Qiagen, Valencia, CA) according to the manufacturer's instruction.
2.2.3. cirDNA modiﬁcation proﬁling
Large-scale cirDNA epigenetic modiﬁcation proﬁles were assessed
according to previously described methods [1]. Brieﬂy, universal DNA
adaptors were ligated to the ends of cirDNA fragments, followed by di-
gestion with DNAmodiﬁcation-sensitive enzymes and ampliﬁcation by
adaptor-mediated PCR (Fig. 2).
2.2.4. Microarray hybridization and processing
The enriched differentially cirDNA modiﬁed fraction was
fragmented, biotin-labeled, and hybridized on Affymetrix GeneChip
Mouse Promoter Array 1.0R (Affymetrix, Santa Clara, CA) and scanned,
according to the manufacturer's protocol. The array consisted of over
4.6 million probes tiled to interrogate over 28,000 mouse promoter re-
gions. Promoter regions were selected from annotated genes in public
databases (33,559 Ensembl genes (version 30_33f), 18,167 RefSeq
mRNAs (NCBI GenBank) and 27,707 complete-CDS mRNAs (NCBI
GenBank)). Probes were 25-mer long, leaving 10-mer separation be-
tween adjacent probes, providing a 35 base pair resolution. Each pro-
moter region was cover by a 10 kb segment.
2.2.5. Microarray data analysis
Microarray raw and processed data were deposited in NCBI's Gene
Expression Omnibus (GEO) database (accession number: GSE61070).
Raw ﬁles (.cel) were produced using GCOS 1.3 software (Affymetrix).Fig. 3. Signal intensity correlation among arrays before normalization. Paired scatter plots of sign
array are plotted in the X- and Y axes, respectively. Red line depicts the correlation trend linesData quality control. Data quality control was performed using the
STARR package [5] in the R statistical environment (version 3.0.2) [6].
Probe annotation was provided by the manufacturer (Mm_PromPR_
v02-1_NCBIv36.bpmap ﬁle; Affymetrix). The absence of hybridization
artifacts was veriﬁed by building pseudoimage plots for each array.
Paired scatter plots were produced to determine the signal distribution
correlation between each array (Fig. 3). Signal distributions before and
after normalizationwere assessed bydensity plots, aswell as the correc-
tion of bias due to GC-content differences (Supplementary Fig. S2 in
[[2]]). Microarray signals in each microarray were loess-normalized
and M–A plots produced to detect technical variation that may mask
true biological differences [7] (Fig. 4). No outliers were detected and
all arrays were included in the assessment of differential cirDNA
modiﬁcation.Assessment of differential cirDNA modiﬁcation. Data were analyzed using
the Partek Genomic Suite Software (PGS) (St. Louis, MO). Signals were
adjusted according to the probe sequence and background corrected
using the Robust Microarray method (RMA)[8]. One-way ANOVA was
used to detect probes showing differential cirDNA modiﬁcation be-
tween the groups. The signiﬁcance level was set at p b 0.05 and fold
changes higher than 2. Model-based analysis of tiling-arrays (MAT) [9]
was used to identify regions of differential cirDNAmodiﬁcation by com-
bining adjacent probes showing signiﬁcant differences between the
groups. A sliding window of 500 bp was set, according to the average
size of the fragments produced in the amplicon preparation step [1].al intensity for each array in the set. Signal intensity values (before normalization) for each
. Correlation coefﬁcient for each pair is indicated.
Fig. 4. Probe-wise signal intensity differences among arrays after Loess-normalization. M–A plots of normalized signal intensity for each possible pair of microarrays in the set. X-axis rep-
resents the mean average of the normalized signal intensity (A = [log2(signal array1) + log2(signal array2)] ∗ 1/2). Y-axis represents the log ratios of the normalized signal intensity
(M= log2(signal array 1)− log2(signal array 2)). The loess lines and the horizontal axis (M = 0) are shown in red and blue, respectively. The inter-quartile range (IQR) and median
are reported for each comparison.
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